Dyne Therapeutics, Inc. DYN
17.91 USD +0.61 (+3.53%)
Nov 3, 2026, 3:52 PM EST
17.32 Day range 18.15
14.25 52-week range 26.78
- YTD
- -8.44%
- 1 year
- -25.72%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 34.33 +91.7% upside
Now 17.91
- Target (low)
- 10.00
- Target (mean)
- 34.33
- Target (high)
- 50.00
Ratings (0m) 17 15 buy · 1 hold · 1 sell
- Strong buy3
- Buy12
- Hold1
- Sell0
- Strong sell1
Recommendation trend
- This month 17
- 1 month ago 17
- 2 months ago 17
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.88189 | -1.09 – -0.65 | -0.76 | -16.0% | 0 | 0.0% | 14 |
| Next quarter | -0.90689 | -1.11 – -0.58 | -0.73 | -24.2% | 0 | 0.0% | 14 |
| Current year | -3.53 | -3.94 – -2.84 | -3.47 | -1.7% | 0 | 0.0% | 15 |
| Next year | -3.31 | -4.53 – -2.75 | -3.53 | +6.1% | 53.40M | 0.0% | 13 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Oppenheimer | Downgrade | Outperform | Perform |
| Sep 30, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Sep 30, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 29, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Sep 9, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Sep 9, 2026 | JP Morgan | Downgrade | Neutral | Underweight |
| Sep 9, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Sep 9, 2026 | Baird | Maintained | Outperform | Outperform |
| Jul 31, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jul 30, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jul 23, 2026 | Cantor Fitzgerald | Initiated | — | Overweight |
| Jun 26, 2026 | TD Cowen | Initiated | — | Buy |
| May 15, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| May 13, 2026 | Bernstein | Maintained | Market Perform | Market Perform |
| Mar 9, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Mar 3, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Mar 3, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Mar 3, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jan 20, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Dec 15, 2025 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Dec 11, 2025 | Stifel | Maintained | Buy | Buy |
| Dec 10, 2025 | Oppenheimer | Upgrade | Perform | Outperform |
| Dec 9, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Dec 9, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Dec 8, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 14, 2025 | JP Morgan | Maintained | Neutral | Neutral |
| Nov 12, 2025 | Oppenheimer | Maintained | Perform | Perform |
| Nov 6, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 6, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 10, 2025 | Oppenheimer | Downgrade | Outperform | Perform |